Development of Antihypertensive Therapies for Use in Pediatric Patients

​Workshop Dates
Wednesday, July 15, 2026
9 a.m.-5 p.m.

​Thursday, July 16, 2026
9-11:30 a.m.

​Workshop Location
FDA White Oak Campus
Building 31, Conference Center, The Great Room (Room 1503)
10903 New Hampshire Ave.
Silver Spring, MD 20993

​Organized By
CDER Office of New Drugs, Division of Pediatrics and Maternal Health
M-CERSI

​Background and Synopsis
Treatment of chronic hypertension in pediatric patients, particularly children from birth to under 6 years of age, remains an area of unmet medical need, with limited FDA-approved therapies for use in this age group. Products are also being developed for the treatment of uncontrolled and/or resistant hypertension in adults. This public workshop will bring together key stakeholders, including clinicians, academicians, regulators, industry, and patients/caregivers, to discuss the similarities and differences in disease pathophysiology and drug response across age groups, determine the extent to which efficacy can be extrapolated, identify development priorities for both initial therapy and uncontrolled hypertension, and explore feasible strategies to generate evidence for the safe and effective use of antihypertensive treatment(s) in pediatric patients with hypertension.

​Agenda
The full agenda is available here.

​Visiting the FDA Campus
Entrance for the public workshop participants (non-FDA employees) is through Building 1, where routine security check procedures will be performed. For parking and security information, please refer to Public Meeting Information, Getting to the FDA, and Visitor Parking and Campus Map.

​Virtual Attendance Information
This workshop will be hybrid. The Zoom link will be provided to all registered attendees via email before the workshop.

​Food & Drink
Attendees may bring their own food and drink; however, the FDA cannot guarantee the use of a refrigerator or microwave. Restaurants near the FDA White Oak campus are available, but before leaving, meeting attendees should consider the amount of time needed to return to campus and go through security screening.

​Accessibility
The FDA will make every effort to accommodate persons with physical disabilities or special needs at public meetings. If you require accommodations due to a disability, email [email protected] at least 14 days before a public meeting. The FDA White Oak campus and FDA shuttle are generally accessible to people with physical disabilities.